Enliven Therapeutics
ELVN· Manufacturing· Fiscal year ends in December
Richard Fair, M.B.A. is the CEO of Enliven Therapeutics.
Executives4
See all- 1Sam Kintz, M.B.A.Former President and Chief Executive OfficerFY2025
- 2Helen CollinsChief Medical OfficerFY2025
- 3Ben HohlChief Financial OfficerFY2025
- 4Richard Fair, M.B.A.President and Chief Executive OfficerNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allEnliven Therapeutics paid its 3 named executives $15.9M in total in FY2025 (Dec).
| Name | |||
|---|---|---|---|
| Sam Kintz, M.B.A.Former President and Chief Executive Officer | |||
| Helen CollinsChief Medical Officer | |||
| Ben HohlChief Financial Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Enliven Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- Lori Kunkel, M.D.Director · 1 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Scott GarlandDirector · -1 yr on the boardNot independentNominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 27, 2026 | FY2025 |
| Annual report | 10-K | Mar 3, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Mar 13, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 14, 2024 | FY2023 |
